PNC Financial Services Group Inc. Has $149,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT

PNC Financial Services Group Inc. decreased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 19.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,335 shares of the biotechnology company’s stock after selling 556 shares during the period. PNC Financial Services Group Inc.’s holdings in Sarepta Therapeutics were worth $149,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in the business. Farallon Capital Management LLC grew its stake in Sarepta Therapeutics by 11.1% in the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock valued at $348,368,000 after acquiring an additional 285,100 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Sarepta Therapeutics by 0.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,956,583 shares of the biotechnology company’s stock valued at $237,901,000 after purchasing an additional 10,343 shares in the last quarter. Alkeon Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 34.7% in the fourth quarter. Alkeon Capital Management LLC now owns 853,845 shares of the biotechnology company’s stock valued at $103,819,000 after purchasing an additional 220,000 shares in the last quarter. Northern Trust Corp lifted its holdings in Sarepta Therapeutics by 22.6% during the fourth quarter. Northern Trust Corp now owns 803,511 shares of the biotechnology company’s stock worth $97,699,000 after acquiring an additional 147,874 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in Sarepta Therapeutics by 438.0% during the first quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company’s stock worth $45,477,000 after acquiring an additional 580,123 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Down 3.8%

SRPT opened at $20.99 on Tuesday. The business has a 50 day simple moving average of $19.37 and a two-hundred day simple moving average of $52.46. Sarepta Therapeutics, Inc. has a one year low of $10.41 and a one year high of $144.22. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81. The firm has a market capitalization of $2.05 billion, a price-to-earnings ratio of -24.13 and a beta of 0.46.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%. The firm had revenue of $611.09 million during the quarter, compared to analyst estimates of $530.66 million. During the same quarter in the prior year, the company earned $0.07 EPS. The business’s revenue was up 68.4% compared to the same quarter last year. Analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on SRPT shares. The Goldman Sachs Group raised their target price on Sarepta Therapeutics to $19.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. TD Cowen cut Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $24.00 price target for the company. in a research report on Wednesday, June 18th. Baird R W cut Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 18th. Guggenheim reduced their target price on Sarepta Therapeutics from $112.00 to $98.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Finally, Scotiabank upgraded Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 price objective for the company in a report on Friday, June 6th. Six research analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics currently has an average rating of “Hold” and a consensus target price of $43.63.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.